TR1X
Tr1x develops cellular therapies intended for the treatment of autoimmune disorders. The company utilizes its exclusive platform to produce cutting-edge cell therapy products designed to recalibrate the immune system and reinstate homeostasis, ultimately fostering long-term tolerance.
TR1X
Social Links:
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2018-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.tr1x.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
75 M USD
Technology used in webpage:
CrUX Dataset CrUX Top 50m
Similar Organizations
Allumeros BioScience
Allumeros BioScience develops and researches on therapeutic and diagnostic advancements for treatment of cancer cells.
Auctus Surgical
Auctus Surgical is developing a dynamic Vertebral Body tethering system for the treatment of pediatric scoliosis.
Cell Receptor
Cell Receptor develops a future-oriented therapy for high medical needs: cancer and autoimmune diseases
Pediatric Bioscience
Pediatric Bioscience develops products to improve the diagnosis and treatment of children with autism and autism spectrum disorders.
SetPoint Medical
SetPoint Medical treats patients with debilitating inflammatory diseases using proprietary implantable bioelectronic devices.
Stem Cell Medicine
Stem Cell Medicine is a developer of cellular therapies in tissue repair and for the treatment of inflammatory disorders.
Tachyon Therapeutics
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.
Investors List
The Column Group
The Column Group investment in Series A - Tr1x
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Tr1x
Neva SGR
Neva SGR investment in Series A - Tr1x
Neva SGR
Neva SGR investment in Series A - Tr1x
Official Site Inspections
http://www.tr1x.bio
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Tr1x"
About Us | Tr1x
Prior to Tr1X, David was Co-Founder and COO of Arine, a therapeutic optimization company he helped launch and scale to serve millions of patients across the US. Before that, he worked at …See details»
Tr1x - Crunchbase Company Profile & Funding
Tr1x may be growing as it has recently unveiled a significant funding round of $75 million, which is indicative of investor confidence and provides capital for …See details»
Careers - tr1x.bio
Tr1X is building a diverse, bold, agile and collaborative organization. Join us to work with leading experts in the field and bring novel, life-changing therapies to patients. ... Graphite Bio co-founder debuts Treg cell therapy startup with …See details»
Tr1x Company Profile 2024: Valuation, Funding
Tr1x General Information Description. Developer of cell therapies intended for the treatment of autoimmune disorders. The company advances in genetic engineering with T- cell biology exploration to develop scalable, effective …See details»
Tr1X - LinkedIn
Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases.See details»
Tr1X - BioSpace
Jan 18, 2024 Tr1X is a private, clinical-stage biotechnology company focused on developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory …See details»
Tr1x, Inc. - Drug pipelines, Patents, Clinical trials - Synapse - Patsnap
Investor/Media Contacts:[email protected] LifeSci AdvisorsChuck [email protected] . Cell Therapy Immunotherapy IND Clinical …See details»
Tr1X, Inc. Announces $75 Million Series A Financing to ... - BioSpace
Jan 17, 2024 About Tr1X Tr1X is a privately held biotechnology company focused on engineering cures for immune and inflammatory diseases. Founded by industry veterans, …See details»
Tr1X - Company Profile & Staff Directory - ContactOut
Tr1X Inc. (pr. "Trix") is a biotechnology company dedicated to the development of novel cellular immunotherapies for patients with autoimmune and inflammatory diseases. The Company …See details»
Science | Tr1x
Tr1X was established to translate key academic discoveries in T-regulatory type 1 (Tr1) cell function and biology into commercially available treatments. 2009. Tr1 Cells . Tr1 Cells are found in patients with tolerance following allogeneic stem …See details»
Tr1X, Inc. Announces $75 Million Series A Financing to Develop …
Tr1X, Inc. today announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T (Treg) and CAR-Treg cell therapies to the clinic to treat …See details»
Cell Therapy Startup Tr1X Emerges from Stealth with $75M
Jan 18, 2024 Pictured: Cell therapy concept/iStock, Meletios Verras. Tr1X came out of stealth mode on Wednesday with $75 million in Series A funding as it looks to bring allogeneic …See details»
Press Release Distribution and Management - GlobeNewswire
Jul 10, 2024 Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy July 10, 2024 08:00 ET | Source: …See details»
Tr1x, a new biotech, joins ‘Treg’ chase with $75M fundraise
Jan 17, 2024 Biotechnology company Tr1x on Wednesday became the latest startup to raise tens of millions of dollars in venture funding to develop a new type of cell therapy for …See details»
Tr1X Announces FDA Clearance of First Investigational New Drug ...
Apr 10, 2024 www.Tr1X.com (PRNewsfoto/Tr1X, Inc.) "The FDA's clearance of our IND for TRX103, the first ever allogeneic engineered Tr1 regulatory T cell product, is an important …See details»
Tr1X Announces FDA Clearance of First Investigational New Drug ...
Apr 10, 2024 For more information visit www.tr1x.bio. Investor Contact: Tr1X Investor Relations [email protected] Media Contact: Julie Normart [email protected] SOURCE Tr1X, Inc.See details»
Our Programs | Tr1x
Graft versus Host Disease (GvHD) occurs due to pathogenic immune responses after hematopoetic stem cell transplants, frequently the only treatment for patients with aggressive …See details»
Tr1X Announces First Patient Dosed in Proof of Concept GvHD …
Tr1X Bio . Wed, Jul 10, 2024, 8:00 AM 3 min read. Tr1X Bio. TRX103 is designed to reset the immune system, improve clinical outcomes, and potentially cure patients suffering from …See details»
News - tr1x.bio
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure …See details»